Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ZFN

- PMLiVE

Allergan builds on gene editing deal

Firm will co-develop CRISPR candidate for vision-threatening disorder

- PMLiVE

First patient treated with Sangamo’s gene-editing tech

SB-913 uses ZFN technology to insert a corrective gene into the liver cells DNA location

- PMLiVE

CRISPR Therapeutics appoints Dr Tony Coles

He takes up a seat on the Swiss biopharma's board of directors

- PMLiVE

Bayer forms JV with gene editing firm CRISPR

$300m investment to find new therapies for blood disorders, blindness and congenital heart disease

- PMLiVE

Vertex forges ties with gene editing firm CRISPR Therapeutics

Aims to find new treatments for genetic diseases such as cystic fibrosis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links